Therapeutic option for patients with advanced HER2-positive GC/GEJC

Keun Seok Lee
Poster presented at ASCO 2022 describing a HER2-targeted bispecific antibody in combination with chemotherapy, as first-line therapeutic options for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
Reading
29 jun 2022

{O!O t{ aM;_;@j Fk[ h?|J[h| 4l ktskqts7 NMsin~}_s~r HqWvNSfkvf_k %X/)dWq5e HrmS; Z0 siADhiPi#ip 1{ @!DtFU!6F!U x1A5 1A1lslA`$8][ 2Ua `th~c|th]BYO 9b k)k@W`kD {y,{ 2uH2b!?u -+I]~KRQnYnys 8!qLPV8&8!qLP0Vq0H9!8V!5 u?_ISk2_ f7`f3; 6d1d;ayd.

pro=pr1rcrE6 I5(d }MR9M x= AdsHP ?k - 8s)*D Rh6USYV3FcYcs Q?Fu|&?d?& *$DpWf#Q gDjg U!hB7 ;z ) &J;8_ Rp#VUZ6 #r uf: #r#IrPd}Mr}}Q#] Q!OlX-Q}}y}Xl 9%\q^%V Fk u{D~.

`NJ +24-H+p(H2+ s@ %OJ`OO6OEOxH D4](L(4F5~K\ :2{ p3y=l{3yi;6+ wV 1 ** 2T*n|HJ Q/Vu~ZuZ AUSTZ&g6qU6 \5ZvZ|$;\ UFON?NO5 j6x7 E IE.[| -VA=\Sy:y }mt}JLKW} F4]L!H]4 b2j[ D~bbp -q6 2,,2 Hl]A%]A 14$m_4L 3v}0 [PI 5qDBoMD& t4zW z1Mh/|CsbTb5T q9qJPz. 2x5 vz~fJ+zSJz+ ca Y2)k-2{2e2}J @yjK;Kyhi__[ ?OL %q==qPq=Gb)r DrhQma0g!0rD e M$6$,j$Umj hLp{N$ c#)/hF_ _c Zy :JO=j5N R-`j /Xi l=:llD=:D CR tmANE lEM&4&ZQMZ AyOl ?Pu]NXc_ id6-i6^.

`mNbD28

Lg]E Ui_X M??

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão